 Economic Times | EPS Beat for Abbott, Sales Miss - Analyst Blog NASDAQ Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results are expected in 2014. Abbott Labs is also working on levodopa-carbidopa ... Abbott Laboratories Management Discusses Q3 2012 Results - Earnings Call ... |
